Hematología y Hemoterapia

Resultados: 387
Tipo Título / Nombre Autor(es) Año
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry Labrador J, Martínez-Cuadrón D, de la Fuente A, Rodríguez-Veiga R, Serrano J..., Bergua JM, et al 2022
Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain Ribera JM, García O, Buendía-Ureña B, Terol MJ, Vicent A..., Bergua J, et al 2022
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma Encinas C, Hernández-Rivas JÁ, Oriol A, Rosiñol L, Blanchard MJ..., Cabrera C, et al 2022
Biomarker-driven phase Ib clinical trial of OPB-111077 in acute myeloid leukemia Martínez López J, Montesinos P, López Muñoz N, Ayala R, Martínez Sánchez P..., Bergua Burgues JM, et al 2022
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M..., Bergua-Burgués JM, et al 2022
The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Morschhauser F, Sehn LH, Friedberg JW, Trneny S ..., Bergua Burgues JM 2021
Long-Term Subgroup Analyses from Azacitidine Vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the Pethema Registry Labrador J, Fuente A de la, Martínez-Cuadrón D, Rodríguez-Veiga R..., Bergua Burgues JM 2021
Patterns of Salvage Therapy in Patients with Acute Myeloid Leukemia Treated Upfront with Azacitidine or Decitabine: Results from the Pethema AML Registry Labrador J, Fuente A de la, Martínez-Cuadrón D, Rodríguez-Veiga R..., Bergua Burgues JM 2021
Integrated Multidimensional Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) to Reconstruct Evolutionary Paterns from Dysplasia to Acute Myeloid Leukemia (AML) Simoes CP, Chillon C, Martínez -Cuadrón D, Calasanz JM..., Bergua Burgues JM 2021
First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Belada D, Kopeckova K, Bergua Burgues JM, Stevens D 2021